Incidence, clinical and biological associations of anti-ADA antibodies
| Disease | Detection method | Patients (n) | ADA dose | Period (weeks) | ADAb (%) | Association with serum trough ADA level | Association with clinical response | Association with AEs | Association with MTX | Reference |
|---|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | ELISA | 30 | 40 mg s.c. eow for 16 weeks | 56 | 4.9 | NR | NR | NR | NR | van der Bijl et al90 |
| RIA | 148 | 40 mg s.c. eow to 40 mg/w | 156 | 28 | Negatively associated (p<0.001) | Negatively associated (p<0.001) | NR | Negatively associated with the use (p<0.001) and the dose (p=0.005) | Bartelds et al91 | |
| ELISA | 434 | 20 or 40 mg eow or 20 or 40 mg/w | 26 | 12 | NR | Negatively correlated | No | NR | Van de Putte et al92 | |
| ELISA | 419 | s.c. 40 mg eow or 20/w | 52 | 0.72 | NR | NR | NR | NR | Keystone et al93 | |
| ELISA | 15 | s.c. 40 mg eow | 45 | 87 | NR | NR | NR | NR | Bender et al94 | |
| RIA | 121 | 40 mg s.c. eow | 28 | 17 | Negatively associated (p<0.001) | Negatively associated (p=0.032) | NR | Negatively associated (p=0.003) | Bartelds et al30 | |
| RIA | 34 | 40 mg s.c. biweekly | 12 | 25 | NR | Negatively associated | NR | NR | Radstake et al75 | |
| 26 | 30 | |||||||||
| RIA | 235 | 40 mg s.c. eow to 40 mg/week | 28 | 20 | NR | Negatively associated (p<0.0001) | NR | Negatively associated (p<0.0001) | Bartelds et al95 | |
| ELISA | 271 | s.c. 20, 40 or 80 mg eow | 24 | 1 | NR | NR | NR | NR | Weinblatt et al8 | |
| Ankylosing spondylitis | NR | 35 | 40 mg eow | 26 | 31 | Negatively associated | Negatively associated (p=0.012) | NR | NR | de Vries et al22 |
| Psoriatic arthritis | RIA | 22 | 40 mg eow | 52 | 18 | Negatively associated (p=0.031 at 12 months) | Negatively associated | NR | NR | Van Kuijk et al96 |
| Psoriasis | RIA | 29 | 40 mg eow after induction 80/40 mg | 24 | 45 | Negatively associated (p<0.001) | Negatively associated (p<0.001) | NR | No patients with MTX developed ADAb (no statistical analysis) | Lecluse et al97 |
| NR | 825 | 40 mg eow | 52 | 8.8 | NR | Negatively associated | No | NR | Menter et al17 | |
| ELISA | 280 | 80 or 40 mg eow | 16 | 6 | NR | Negatively associated | No | NR | Papp et al98 | |
| Crohn's disease | ELISA | 130 | 40 mg eow to 40 mg/w | 220 | 9.2 | Negatively associated (p<0.0001) | No | No | No | Karmiris et al99 |
| NR | 225 | 40 mg w0/20 w2, or 80/40, or 160/80 | 4 | 0.04 | NR | NR | NR | NR | Hanauer et al100 | |
| RIA | 30 | s.c.160 mg at w0, 80 mg w2, and 40 mg/2 w | 90 | 17 | NR | Negatively associated (p=0.006) | NR | No | West et al101 | |
| NR | 269 | s.c. 40 mg eow or weekly | 55 | 2.6 | NR | No | NR | No ADAb with the use of IS (MTX, AZA, 6-MCP) (no statistical analysis) | Sandborn et al16 |
6-MCP, 6-mercaptopurine; ADA, adalimumab; ADAb, antidrug antibodies; AEs, adverse events; AZA, azathioprine; eow, each other week; IS, immunosuppressive agent; MTX, methotrexate; NR, not reported; RIA, radioimmunoassay; s.c., subcutaneous; w, week.